Home » Topics » Regulatory » EMA

EMA
RSS

Genta receives EMA advice for phase III tesetaxel trial in gastric cancer

Nov. 3, 2010

E.U. grants authorization for Ruconest in hereditary angioedema

Oct. 29, 2010

EMA recommends changes in prescribing information for Invirase

Oct. 26, 2010

CHMP recommends new indication for Bristol-Myers Squibb's Sprycel

Oct. 26, 2010

CHMP recommends variation of marketing authorization for Pfizer's Sutent

Oct. 26, 2010

CHMP recommends marketing authorization for MedImmune's FluEnz vaccine

Oct. 26, 2010

CHMP issues positive opinion on ranibizumab for DME-related vision impairment

Oct. 25, 2010

EMA initiates review of Orion's centralized MAA for dexmedetomidine

Oct. 22, 2010

EC grants orphan drug status for nafamostat mesilate in cystic fibrosis

Oct. 21, 2010

Roche files to extend indication of tocilizumab for systemic juvenile idiopathic arthritis

Oct. 21, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...